A Study to Investigate Safety and Effectiveness of Tacabrutideg (BGB-16673) in Combination With Other Agents in Participants With Relapsed or Refractory B-Cell Malignancies
Recruiting · Phase 1, Phase 2 · NCT06634589
Conditions: B-cell Malignancy, Relapsed Cancer, Refractory Cancer, B-cell Lymphoma
At a glance
- Research payments reported, 2025
- $3.3M
- U.S. investigators named
- 15
- Sites paid
- 18
- Planned or actual enrollment
- 80
About the trial
- Sponsor
- BeOne Medicines
- Tested
- Tacabrutideg (drug), Sonrotoclax (drug), Zanubrutinib (drug), Mosunetuzumab (drug), Glofitamab (drug), Obinutuzumab (drug)
- Dates
- Started 2024-11-27; completion 2029-12-02
- Results posted
- Not yet
The purpose of this study is to measure the safety, preliminary antitumor activity, pharmacokinetics, and pharmacodynamics with tacabrutideg in combination with other agents in participants with relapsed or refractory (R/R) B-cell malignancies. This study is structured as a master protocol with separate substudies. This study currently includes four substudies, and more substudies may be added as other combination agents are identified.
From ClinicalTrials.gov, last updated 2026-09-11. Full record, eligibility and contacts (opens in a new tab)
Industry funding
Beone Medicines Ltd. reported $3.3M in research payments for this study in 2025 (243 payments).
Products named: Brukinsa
Research payments usually go to hospitals, universities and research sites to run a study, not to the investigators personally. A payment is not evidence of wrongdoing.
U.S. investigators named on this study
- Talal Hilal, M.D. Hematology & Oncology · Phoenix, AZ
- Kevin R. Kelly, M.D. Hematology & Oncology · Los Angeles, CA
- Julio C. Chavez, MD Hematology & Oncology · Tampa, FL
- Ricardo D. Parrondo, M.D. Hematology & Oncology · Jacksonville, FL
- Marc S. Hoffmann, MD Hematology & Oncology · Overland Park, KS
- Yucai Wang, MD, PHD Hematology & Oncology · Rochester, MN
- Brad S. Kahl, MD Medical Oncology · Saint Louis, MO
- John N. Allan, M.D. Hematology & Oncology · New York, NY
- Adam S. Kittai, M.D. Hematology · New York, NY
- Meghan C. Thompson, MD Hematology & Oncology · New York, NY
- Danielle S. Wallace, M.D Hematology & Oncology · Rochester, NY
- Narendranath Epperla, MD Hematology · Columbus, OH
- Marcus Messmer Medical Oncology · Philadelphia, PA
- Nitin Jain, MD Internal Medicine · Houston, TX
- Saurabh Rajguru, M.D Hematology & Oncology · Madison, WI
Clinicians the company named as principal investigators in its Open Payments reports.
Sites paid to run it
- Moffitt Cancer Center $741,932
- Fox Chase Cancer Center $406,726
- Icahn School of Medicine at Mount Sinai $399,478
- Ut MD Anderson Cancer Center $245,568
- Huntsman Cancer Institute $179,287
- The Board of Regents of the University of Wisconsin System $172,125
- Memorial Sloan Kettering Cancer Center $167,745
- Mayo Clinic Scottsdale $152,631
- Washington University School of Medicine Siteman Cancer Center $134,064
- Strong Memorial Hospital, NY $131,455
- University of Southern California, Norris Comprehensive Cancer Center $127,591
- Weill Cornell Medical College $125,862
- University of Kansas Medical Center Research Institute, Inc. $92,057
- University of Utah Hospital and Clinics, UT $75,545
- Mayo Clinic Hospital, AZ $58,396
- Mayo Clinic Jacksonville $36,360
- Mayo Clinic Hospital Rochester, MN $33,536
- Washington University $7,250
Sources: CMS Open Payments research payments (program year 2025) and ClinicalTrials.gov, U.S. National Library of Medicine.